Clinical trial
Maintenance Intermittent Therapy for Symptomatic GERD Patients
NCT00165841 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00165841 |
|---|---|
| Title | Maintenance Intermittent Therapy for Symptomatic GERD Patients |
| Official title | A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease |
| Intervention type | Drug |
| Interventions | Rabeprazole 20 mg |
| Enrollment | 200 |
| Start date | Oct 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Jun 1, 2008 |
| First posted | Sep 14, 2005 |
| Last update posted | May 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: